Sign up for the Industry Watch newsletter and never miss a story again.

Yes, sign me up
Kevin Thornton
Kevin Thornton
4 min. read

It’s week 3 of January 2020. Our stories for this edition of Industry Watch include; the potential discovery of a new virus in China; a new research drive to find a cure for Motor Neuron Disease; the finding of a new auto-inflammatory disease; and the New York Times story of the child who is the center of the break through gene therapy for Sickle Cell Disease.

WHO Says Mysterious Illness in China Likely Being Caused by New Virus

The World Health Organization confirmed on Wednesday that Chinese authorities believe a new coronavirus—from the family that produced SARS and MERS—may be the cause of mysterious pneumonia cases in the city of Wuhan.

The Immune Cells Inside Tumors Hint at a New Way to Treat Cancers

A type of immune cell has been found inside tumors that helps our bodies mount attacks against cancer. Boosting these cells may lead to a new kind of treatment.

Scientists Discovered ‘Mini-Computers’ in Human Neurons – That’s Great News for AI

The neurons in our cortex, the outermost “crust” of our brain, seem to have uniquely evolved to sustain complex computations in their input cables.

Motor Neurone Disease: The Search for New Treatments

A major study will assess if new - and existing - drugs can help people with motor neurone disease.

Probiotic Drink Could Hold the Key to Antibiotic Resistance

Scientists at the University of Birmingham have engineered a probiotic drink that can potentially combat drug resistant bacteria.

Researchers Discover a New Auto-Inflammatory Disease called CRIA Syndrome

A new auto-inflammatory disease called CRIA syndrome causes inflammation-related symptoms including fever, swollen lymph nodes, and in some cases...

A Teenager’s Breakthrough Gene Therapy for Sickle Cell Disease

Doctors reset Helen Obando’s DNA in an effort to cure her of a painful genetic blood disorder. She’s the youngest person to receive the treatment.

You have challenges. We have solutions.

Start a conversation